NetworkNewsBreaks

TuesdayNov 26, 2024 12:30 pm

NetworkNewsBreaks – Alphabet Inc. (NASDAQ: GOOGL) Faces Legal Challenges but Remains Financially Robust

Alphabet (NASDAQ: GOOGL, GOOG) is currently navigating a significant legal challenge as it advances to the next stage in its second monopoly trial, led by the U.S. Department of Justice (“DoJ”). This trial scrutinizes Google’s advertising technology, with closing arguments recently concluded. A ruling by U.S. District Court Judge Leonie Brinkema is expected by the end of 2024. If deemed a monopoly, a subsequent trial will address potential remedies. The DoJ’s actions, supported by multiple U.S. states, aim to curb monopolistic practices in the tech industry, potentially impacting Google’s services and reshaping online information access. This legal scrutiny comes amid…

Continue Reading

TuesdayNov 26, 2024 11:30 am

NetworkNewsBreaks – Torr Metals Inc. (TSX.V: TMET) Identifies High-Priority Gold Targets at Filion Gold Project

Torr Metals Inc. (TSX.V: TMET) announced the successful completion of its 2024 surface geochemical exploration program at the 100%-owned Filion Gold Project in northern Ontario, collecting 1,092 soil and 44 rock grab samples. The program expanded exploration at Filion West with a comprehensive 8.8 km² soil sampling grid, uncovering multiple high-priority zones influenced by advanced LiDAR technology. Highlights include 17 undocumented historical trenches and gold grades of up to 91.4 g/t Au in chip samples. Filion East was confirmed to share favorable geology with Filion West, extending prospectivity across the 42 km-long Filion Fault system. With drilling permits secured and…

Continue Reading

TuesdayNov 26, 2024 11:17 am

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Partners with Emerald and Papé to Launch Refrigerated EV Truck Solution

Mullen Automotive (NASDAQ: MULN), announced a collaboration with Emerald Transportation Solutions and the Papé Group to develop a refrigerated ("reefer") upfit for the Mullen THREE, its Class 3 all-electric truck. Designed for perishable goods transportation, the versatile Mullen THREE offers a clean top-of-rail chassis for custom upfitting, supporting payloads over 5,300 lbs. This innovative solution aligns with Mullen’s goal of delivering sustainable transportation options for industries like frozen food, grocery, and beverage delivery. Additionally, the Mullen THREE and Mullen ONE models are eligible for state and federal incentives, offering substantial cost savings for fleet operators. To view the full press…

Continue Reading

TuesdayNov 26, 2024 9:31 am

NetworkNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Reports High-Grade Mineralization in Santa Barbara Zone of Iska Iska Project

  Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) announced initial assay results from its definition diamond drilling program in the Santa Barbara starter pit area of the Iska Iska silver-tin polymetallic project in Bolivia. Highlighted results from Hole DSB-68 include a 289.13-meter intersection grading 66.90g Ag/t, 0.63% Zn, 0.42% Pb, and 0.11% Sn, with higher-grade intervals reaching up to 126.10g Ag/t over 122.03 meters. The drilling confirms large high-grade mineralized shoots within breccia pipes that serve as feeders, with mineralization widening at depth. These results align with the geological zoning model of Bolivia's Tin Belt and suggest the potential…

Continue Reading

TuesdayNov 26, 2024 8:40 am

NetworkNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Highlights Giuseppe Rossi’s Pepito Cup Revival and Community Impact

Brera Holdings (NASDAQ: BREA) announced the return of The Pepito Cup, an annual soccer fan club tournament organized by Advisory Board member Giuseppe Rossi. Held on November 17, 2024, at the Waldwick Superdome in New Jersey and sponsored by the GIUSEPPE ROSSI ACADEMY, the event featured 12 teams competing in a 25-minute match elimination format, with Napoli Club NYC crowned champions. Open to the public and family-friendly, the event reflects Brera Holdings' commitment to fostering community engagement and expanding its global sports footprint through initiatives led by influential figures like Rossi. To view the full press release, visit https://nnw.fm/58wSD About…

Continue Reading

MondayNov 25, 2024 1:23 pm

NetworkNewsBreaks – BioAdaptives Inc. (BDPT) to Proceed with Human Clinical Trial for Zeranovia(TM)

BioAdaptives (OTC: BDPT) today announced its receipt of approval for a human clinical trial of its weight management product, Zeranovia(TM). Approved by an Institutional Review Board, the trial will be managed and supervised by doctors in Las Vegas, Nevada. “According to data from the National Institutes of Health's Office of Dietary Supplements (‘ODS’), less than 1.0% of nutraceuticals sold in the United States undergo examination in human clinical trials,” said BioAdaptives CEO James Keener. “We are committed to supplying the highest quality products with provable scientific results. Zeranovia’s(TM) success is based on a high-protein blend of vitamins, minerals, and five…

Continue Reading

MondayNov 25, 2024 12:05 pm

NetworkNewsBreaks – Sprout Social Inc.’s (NASDAQ: SPT) Strategic AI Investments Amid Financial Challenges

Sprout Social (NASDAQ: SPT) is a prominent player in the social media management software industry. The company focuses on providing cloud-based solutions that help brands manage their social media presence effectively. Sprout’s competitors include companies like Hootsuite and Buffer, but it distinguishes itself with its advanced AI-driven tools. Sprout Social’s recent updates to its AI solutions aim to enhance brand competitiveness and operational efficiency. Despite a negative price-to-earnings (“P/E”) ratio of -28.20, indicating current negative earnings, the company is investing in innovations like “Generate Posts” and “Smart Categories” to streamline social media operations. These tools help brands maintain their voice…

Continue Reading

MondayNov 25, 2024 11:03 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent glioblastoma multiforme (“GBM”). Presented at the 29th Annual Meeting of the Society for Neuro-Oncology, the data show balanced patient demographics and safety profiles between the study arms, with Berubicin showing comparable adverse event rates and promising potential to improve overall survival (“OS”), the trial's primary endpoint. With enrollment completed at 252 patients, CNS expects to report primary analysis data in early 2025. Berubicin holds FDA Fast Track and Orphan Drug Designations, underscoring its significance in…

Continue Reading

MondayNov 25, 2024 10:06 am

NetworkNewsBreaks – HealthLynked Corp. Completes $3 Million Cash Consideration from ACO Health Partners Sale

HealthLynked (OTCQB: HLYK) announced the receipt of $500,000 as part of its contractual share of shared savings generated by ACO Health Partners (AHP) during the 2023 performance period. This marks the final payment under the terms of the January 2023 sale of AHP, bringing the total gross proceeds to $3 million, including $750,000 from the initial sale and $1.75 million in participation-based payments. CEO Dr. Michael Dent highlighted the strategic value of the sale, enabling HealthLynked to focus on advancing its core healthcare technology and patient engagement solutions. To view the full press release, visit https://nnw.fm/lyC0f About HealthLynked Corp. HealthLynked…

Continue Reading

MondayNov 25, 2024 8:25 am

NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates

Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria Maccecchini, the event will highlight updates on Phase 3 studies for Parkinson’s and Alzheimer’s diseases, regulatory milestones, financial strategies, and plans for advancing neurodegenerative therapies in 2025. To view the full press release, visit https://nnw.fm/qFEH9 About Annovis Bio Inc. Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic…

Continue Reading